Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Alfredo Tartarone, Rosa Lerose, Chiara Lazzari, Vanesa Gregorc, Michele Aieta

Research output: Contribution to journalArticlepeer-review

Abstract

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations derive greater benefits from first- and second-generation tyrosine kinase inhibitors (TKIs) than from chemotherapy, especially in the first-line setting. Thus, main treatment guidelines indicate to test all patients with lung adenocarcinoma for these genetic abnormalities and recommend the employment of TKIs in these patients. However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. In the current review, we will analyze the state of EGFR-TKIs therapy in untreated EGFR-mutated NSCLC patients with a focus on both efficacy and toxicity.

Original languageEnglish
Article number78
JournalMedical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • Afatinib
  • Epidermal growth factor receptor
  • Erlotinib
  • Gefitinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?'. Together they form a unique fingerprint.

Cite this